§ Mrs. Maureen HicksTo ask the Secretary of State for Health if he will take measures to ensure that the RU486 abortion pill is not marketed in the United Kingdom, in the light of recent additional evidence.
§ Mrs. Virginia BottomleyBefore the granting of a licence for a new drug in the United Kingdom the applicant must satisfy the licensing authority as to the safety, quality and efficacy of the drug as set out in the Medicines Act and in European directives.
All relevant information, whether or not it is favourable to the application, must be made available to the licensing authority by the applicant as soon as it becomes available.
It is for the manufacturer of any drug to decide whether or not, once a product licence has been granted under the Medicines Act, to market the drug in this country.